This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Cook, D. J. Articles by Oxman, A. D. Search for Related Content PubMed Articles by Cook, D. J. Articles by Oxman, A. D. Social Bookmarking                         What's this?

Does Fibronectin Reduce Mortality in Sepsis? A Meta-Analysis

Departments of Internal Medicine

Jeffrey E. Grossman, MD

Clinical Epidemiology and Biostatistics, McMaster University Medical Centre, Hamilton, Ontario, Canada

Andrew D. Oxman, MD, MSc

Department of Medicine, Division of Respirology, University of Wisconsin Health Sciences Centre, Madison, WI

We examine the effect of fibronectin administration on mortality in sepsis. An English language literature search using MEDLINE, EMBASE, SCISEARCH, and compu terized databases of unpublished research in addition to bibliographic review was performed, and duplicate independent review of 41 articles by two observers identified six relevant randomized clinical trials. Study quality and descriptive information concerning the pop ulation, intervention, and outcome measurements were assessed. Three of six trials demonstrated favorable mor tality trends, but none reached statistical significance. Results of the 282 patients in all six trials yield a com mon odds ratio of 0.97 and a 95% confidence interval of 0.58 to 1.61. These results do not show a statistically significant effect favoring treatment, but neither do they exclude a clinically important benefit. The benefit of fibronectin in decreasing mortality in sepsis is not sup ported by these studies. However, methodological heterogeneity and the possibility of a Type II error, as well as our understanding of the role of fibronectin in the pathophysiology of sepsis, do not allow for a firm negative conclusion regarding the therapeutic efficacy of fibronectin in sepsis. A large, rigorously designed trial should be considered once investigators can reach a consensus regarding current methodological and patho physiological controversies.

Journal of Intensive Care Medicine, Vol. 4, No. 6, 265-271 (1989)
DOI: 10.1177/088506668900400604


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?